1. Liver enzyme CYP2D6 gene and tardive dyskinesia
- Author
-
Lu, Justin Y, Tiwari, Arun K, Freeman, Natalie, Zai, Gwyneth C, de Luca, Vincenzo, Müller, Daniel J, Tampakeras, Maria, Herbert, Deanna, Emmerson, Heather, Cheema, Sheraz Y, King, Nicole, Voineskos, Aristotle N, Potkin, Steven G, Lieberman, Jeffrey A, Meltzer, Herbert Y, Remington, Gary, Kennedy, James L, and Zai, Clement C
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biological Sciences ,Biomedical and Clinical Sciences ,Genetics ,Mental health ,Adult ,Antipsychotic Agents ,Cytochrome P-450 CYP2D6 ,Female ,Humans ,Liver ,Male ,Middle Aged ,Schizophrenia ,Tardive Dyskinesia ,White People ,metabolizer phenotype ,pharmacogenetics ,schizophrenia ,tardive dyskinesia ,CYP2D6 ,Medical and Health Sciences ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
Background: Tardive dyskinesia (TD) is an iatrogenic involuntary movement disorder occurring after extended antipsychotic use with unclear pathogenesis. CYP2D6 is a liver enzyme involved in antipsychotic metabolism and a well-studied gene candidate for TD. Materials & methods: We tested predicted CYP2D6 metabolizer phenotype with TD occurrence and severity in our two samples of European chronic schizophrenia patients (total n = 198, of which 82 had TD). Results: TD occurrence were associated with extreme metabolizer phenotype, controlling for age and sex (p = 0.012). In other words, individuals with either increased and no CYP2D6 activity were at higher risk of having TD. Conclusion: Unlike most previous findings, TD occurrence may be associated with both extremes of CYP2D6 metabolic activity rather than solely for poor metabolizers.
- Published
- 2020